Xenoport Inc. (XNPT) announced favorable preliminary results from a Phase 1 clinical trial after the close Thursday. The study was designed to assess the pharmacokinetics, safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate. The stock is now up 0.33 on 6K shares.
Xenoport declined during the first 2 hours of trade Thursday and finished down by 0.15 at $11.15. The stock closed near the middle of a 2 1/2 week range.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.